NCT06929468Recruiting
Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Cancer
Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Squamous Cell Carcinoma: A Cohort Study
Source: ClinicalTrials.gov · Last updated 20 Oct 2026
Brief summary (registry, in English)
The goal of this observational study is to learn about the occurrence of and to identify suitable strategies for screening and monitoring of inner ear damage in patients receiving cisplatin chemoradiotherapy for head and neck cancer. Researchers will compare patients who are receiving cisplatin chemoradiotherapy to patients who are only receiving radiotherapy. Patients will undergo standardized testing for hearing loss, tinnitus and vestibular dysfunction at baseline, during and after treatment. Optional genetic analyses will aim to identify genes known to predispose to cisplatin-induced ototoxicity.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 55 (estimated)
- First submitted
- 7 Apr 2025
- Start date
- 20 Jan 2026
- Primary completion date
- Jun 2027
- Lead sponsor
- Simon Jäger
- Diseases
- Head and neck cancer
- NCT number
- NCT06929468
What you commit to
- Study type: Observational
- Planned participants: 55
- From 20 Jan 2026 to the primary completion date, Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current cochlear implant
- Concurrent treatment with loop diuretics (e.g. furosemide), aminoglycoside antibiotics or other known ototoxic substances in the last three months
Other illness
- Severe hearing impairment (WHO grade 3 or 4, corresponding to an audiometric ISO value of ≥61 dB in the better ear at frequencies of 500, 1000, 2000 and 4000 Hz)
- Acute psychosis or serious psychiatric illness
- Addiction disorder
Other
- Self-reported tinnitus or vestibular dysfunction in the last 3 months (only lead to exclusion of the corresponding secondary objectives, not to complete exclusion from the study)
Who the study is looking for
- Diagnosis of head and neck squamous cell carcinoma
- Cisplatin-based chemoradiotherapy (monotherapy or combination-therapy, adjuvant or neo-adjuvant) or only radiotherapy (control group)
- Age 18 to 85 years
- Signed agreement and willingness to participate in the study and adhere to the study protocol
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Klinikum Nuremberg Coordinator of this site? Confirm its status | Nuremberg | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.